JP2018501273A - オスペミフェン及びフィスペミフェンを調製するためのプロセス - Google Patents
オスペミフェン及びフィスペミフェンを調製するためのプロセス Download PDFInfo
- Publication number
- JP2018501273A JP2018501273A JP2017534591A JP2017534591A JP2018501273A JP 2018501273 A JP2018501273 A JP 2018501273A JP 2017534591 A JP2017534591 A JP 2017534591A JP 2017534591 A JP2017534591 A JP 2017534591A JP 2018501273 A JP2018501273 A JP 2018501273A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- ospemiphene
- phenol
- fispemifen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 claims abstract description 14
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 15
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000002168 alkylating agent Substances 0.000 abstract description 2
- 229940100198 alkylating agent Drugs 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229960003969 ospemifene Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 230000002152 alkylating effect Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 4
- HZPJJMOFPSHKFE-UHFFFAOYSA-N 4-(4-chloro-1,2-diphenylbut-1-enyl)phenol Chemical compound C1=CC(O)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 HZPJJMOFPSHKFE-UHFFFAOYSA-N 0.000 description 4
- NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- -1 aryl sulfonate ester Chemical class 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000002834 estrogen receptor modulator Substances 0.000 description 2
- 229950004684 fispemifene Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 0 *CCOc(cc1)ccc1C(c1ccccc1)=C(CCCl)c1ccccc1 Chemical compound *CCOc(cc1)ccc1C(c1ccccc1)=C(CCCl)c1ccccc1 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FWOHDAGPWDEWIB-UHFFFAOYSA-N 2-bromoethoxymethylbenzene Chemical compound BrCCOCC1=CC=CC=C1 FWOHDAGPWDEWIB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000037867 male androgen deficiency Diseases 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
本発明の目的は、活性成分であるオスペミフェン(ospemifene)及びフィスペミフェン(fispemifene)を調製するためのプロセスである。
その化学名が2−{4−[(1Z)−4−クロロ−1,2−ジフェニル−1−ブテン−1−イル]フェノキシ}エタノール(図面)であるオスペミフェンは、非ステロイド性の選択的なエストロゲン受容体モジュレーター(SERM)であり、これは閉経後に誘発される、外陰部の及び膣の萎縮を処置するために最近承認された医薬の活性成分である。
本発明者らは、驚くべきことに、フェノール4を、式7:
[式中、Xは、脱離基であり、そしてYは、−(OCH2CH2)nOH基(式中、nは、0又は1である)であるか;或いは、X及びYは、一緒になって、酸素原子を表す]で示されるアルキル化剤でアルキル化し、式8:
[式中、Yは、上に定義されるとおりである]で示される化合物を得ることによって、
オスペミフェン及びフィスペミフェンを有利に合成できることを見出した。
式7で示される化合物の脱離基Xは、好ましくは、ハロゲン(例えば、塩素、臭素又はヨウ素)、或いはアルキルの又はアリールのスルホン酸エステル(例えば、メシルオキシ若しくはトシルオキシ)である。
水素化ナトリウム(4.2g)を、不活性ガスの環境中、4−(4−クロロ−1,2−ジフェニル−ブテン−1−イル)フェノール(10g)のテトラヒドロフラン(120mL)中溶液に少しずつ添加し、混合物を室温で1時間、撹拌下で維持する。2−ヨードエタノール(11mL)を滴下して加え、反応混合物を約9時間還流する。水を加え、混合物を濃縮し、酢酸エチルで抽出する。有機相を炭酸ナトリウム水溶液で、次に水で洗浄し、次に減圧下で濃縮する。メタノール−水(約5:1)からの残留物を結晶化した後で、9.9gの粗オスペミフェンを得る。
ナトリウムメチラートのメタノール(6.25mL)中溶液を、不活性ガスの環境中、4−(4−クロロ−1,2−ジフェニル−ブテン−1−イル)フェノール(10g)のメタノール(100mL)中溶液に加え、撹拌下、室温で1時間維持する。混合物を減圧下で濃縮し、テトラヒドロフラン(100mL)に溶かす。2−ヨードエタノール(3.5mL)のテトラヒドロフラン(30mL)中溶液を滴下して加え、反応混合物を約3時間還流する。水を加え、混合物を濃縮し、酢酸エチルで抽出する。有機相を飽和炭酸水素ナトリウム水溶液で、最後に水で洗浄する。次に得られた溶液を減圧下で濃縮し、メタノール−水から結晶化させて、5.8gの粗オスペミフェンを得る。
カリウムtert−ブチラート(2.0g)を、不活性ガスの環境中、4−(4−クロロ−1,2−ジフェニル−ブテン−1−イル)フェノール(5g)のtert−ブタノール(75mL)中溶液に加え、撹拌下、室温で1時間維持する。溶媒を減圧下で濃縮し、濃縮物をテトラヒドロフラン(50mL)に溶かす。2−ヨードエタノール(1.7mL)のテトラヒドロフラン(15mL)中溶液を約30分間で加え、次に反応混合物を約2時間還流する。次に、実施例1に記載されているようにプロセスを続け、2.9gの粗オスペミフェンを得る。
50%水酸化カリウム水溶液(4.4mL)を、不活性ガス環境中、4−(4−クロロ−1,2−ジフェニル−ブテン−1−イル)フェノール(2g)のトルエン(20mL)中溶液に加え、室温で15分間、撹拌下で維持する。2−ヨードエタノール(2.2mL)を約30分間で加え、反応混合物を還流し、その温度で約7時間維持する。水の添加の後、相を分離する。有機相を飽和炭酸水素ナトリウム水溶液で、最後に水で洗浄する。次に有機相を減圧下で濃縮する。メタノール−水(約5:1)からの残留物を結晶化した後に、0.85gの粗オスペミフェンを得る。
Claims (5)
- Xが、塩素、臭素、ヨウ素、メシルオキシ又はトシルオキシより選択される脱離基である、請求項1記載のプロセス。
- 請求項1又は2記載のプロセスであって、Xが、請求項中で定義されるとおりであり、そしてnが、0である、式8(式中、Yは、−OHである)で示される化合物を得るための、プロセス。
- 請求項1記載のプロセスであって、式7で示される化合物において、X及びYが、一緒になって、酸素原子を表す、式8(式中、Yは、−OHである)で示される化合物を得るための、プロセス。
- 請求項1又は2記載のプロセスであって、Xが、請求項中で定義されるとおりであり、そしてnが、1である、式8(式中、Yは、−OCH2CH2OHである)で示される化合物を得るための、プロセス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2014A002267 | 2014-12-29 | ||
ITMI20142267 | 2014-12-29 | ||
PCT/IB2015/060007 WO2016108172A1 (en) | 2014-12-29 | 2015-12-28 | Process for the preparation of ospemifene and fispemifene |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018501273A true JP2018501273A (ja) | 2018-01-18 |
JP6697467B2 JP6697467B2 (ja) | 2020-05-20 |
Family
ID=52574316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017534591A Active JP6697467B2 (ja) | 2014-12-29 | 2015-12-28 | オスペミフェン及びフィスペミフェンを調製するためのプロセス |
Country Status (7)
Country | Link |
---|---|
US (1) | US9975832B2 (ja) |
EP (1) | EP3240771B1 (ja) |
JP (1) | JP6697467B2 (ja) |
CA (1) | CA2972198C (ja) |
ES (1) | ES2717546T3 (ja) |
IL (1) | IL253175B (ja) |
WO (1) | WO2016108172A1 (ja) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
JP2008511615A (ja) | 2004-09-03 | 2008-04-17 | ホルモス メディカル リミテッド | アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質 |
ITMI20050278A1 (it) | 2005-02-23 | 2006-08-24 | Solmag S P A | Procedimento per la preparazione del toremifene |
EP2518039B8 (en) | 2007-02-14 | 2014-12-17 | Forendo Pharma Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
JP5850857B2 (ja) | 2010-01-19 | 2016-02-03 | カンブレックス カルルスクーガ アクチボラゲット | ベンゾフェノン誘導体を産生するための新規な方法 |
CN103242142A (zh) | 2012-02-13 | 2013-08-14 | 天津药物研究院 | 欧司哌米芬及其中间体的制备方法 |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
EP2909163A1 (en) | 2012-10-19 | 2015-08-26 | Fermion Oy | A process for the preparation of ospemifene |
CN104030896A (zh) | 2013-03-07 | 2014-09-10 | 天津药物研究院 | 一种简易去除欧司哌米芬特异杂质的方法 |
-
2015
- 2015-12-28 US US15/539,695 patent/US9975832B2/en active Active
- 2015-12-28 EP EP15830869.2A patent/EP3240771B1/en active Active
- 2015-12-28 ES ES15830869T patent/ES2717546T3/es active Active
- 2015-12-28 CA CA2972198A patent/CA2972198C/en active Active
- 2015-12-28 JP JP2017534591A patent/JP6697467B2/ja active Active
- 2015-12-28 WO PCT/IB2015/060007 patent/WO2016108172A1/en active Application Filing
-
2017
- 2017-06-26 IL IL25317517A patent/IL253175B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL253175A0 (en) | 2017-08-31 |
CA2972198A1 (en) | 2016-07-07 |
EP3240771B1 (en) | 2019-02-20 |
EP3240771A1 (en) | 2017-11-08 |
JP6697467B2 (ja) | 2020-05-20 |
US20170342007A1 (en) | 2017-11-30 |
US9975832B2 (en) | 2018-05-22 |
IL253175B (en) | 2019-11-28 |
WO2016108172A1 (en) | 2016-07-07 |
ES2717546T3 (es) | 2019-06-21 |
CA2972198C (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5850857B2 (ja) | ベンゾフェノン誘導体を産生するための新規な方法 | |
EP3080086B1 (en) | Process of making adamantanamides | |
WO2015049360A1 (en) | Selective hydrolysis and alcoholysis of chlorinated benzenes | |
EP2226317B1 (en) | Aryl (1h-1,2,4-triazol-1-yl) compound, and process for production thereof | |
JP7448532B2 (ja) | ピペラジニル-エトキシ-ブロモフェニル誘導体の新しい合成方法及びそれらを含有する化合物の製造におけるその応用 | |
JP6697467B2 (ja) | オスペミフェン及びフィスペミフェンを調製するためのプロセス | |
JP2009137955A (ja) | シクロアルキルおよびハロアルキルo−アミノフエニルケトン類の改良された製造方法 | |
JP4824564B2 (ja) | ヒドラゾン化合物の製造方法 | |
JP6174156B2 (ja) | オスペミフェンの製造方法 | |
US10683245B2 (en) | Process for manufacturing 1-cyclopropyl-naphthalenes | |
US11753382B2 (en) | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | |
EP3224251B1 (en) | Method for preparation of 2-methyl-1,2-benzisothiazolin-3-one | |
EP2980079A1 (en) | Method of manufacturing pyridazinone compound | |
JP6059157B2 (ja) | モンテルカスト中間体のカンファースルホン酸塩 | |
JP5482233B2 (ja) | ジアリールジスルフィド化合物の製造方法 | |
EP3354645A1 (en) | Process for preparing urolithins | |
RU2702121C1 (ru) | Способ получения производного бензилового эфира 2-аминоникотиновой кислоты | |
JP4709741B2 (ja) | ピリジン−置換アミノケタール誘導体の製造法 | |
WO2009150660A1 (en) | A process for the preparation of arylcyclopropane carboxylic carbonitriles, and compounds derived therefrom | |
JPH08283222A (ja) | 置換アミンの製造方法 | |
CN108137457A (zh) | 苯氧乙醇衍生物的制造方法 | |
JP2018537407A (ja) | クラウンエーテル触媒を利用した、置換クロロアシラールを用いたピコリンアミドのアルキル化 | |
JP2017507989A5 (ja) | ||
JPS6128660B2 (ja) | ||
JPH0797373A (ja) | フェノールエーテルの製造のための環状中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181226 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191008 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200324 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200424 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6697467 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |